What is Elbasvir Oral Granules used for?

Elbasvir Oral Granules is indicated for Chronic hepatitis C virus infection.

Who makes Elbasvir Oral Granules?

Elbasvir Oral Granules is developed by Merck Sharp & Dohme LLC.

What development phase is Elbasvir Oral Granules in?

Elbasvir Oral Granules is in Phase 2.

What are the side effects of Elbasvir Oral Granules?

Common side effects include Fatigue, Headache, Nausea.

Last reviewed 2026-05-14 · How we verify

Elbasvir Oral Granules

Merck Sharp & Dohme LLC · Phase 2 active Small molecule

Inhibits NS5A protein of hepatitis C virus

Inhibits NS5A protein of hepatitis C virus Used for Chronic hepatitis C virus infection.

At a glance

Generic name	Elbasvir Oral Granules
Also known as	MK-8742
Sponsor	Merck Sharp & Dohme LLC
Drug class	NS5A inhibitor
Target	NS5A protein
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Elbasvir is a direct-acting antiviral that targets the NS5A protein of hepatitis C virus, preventing viral replication.

Approved indications

Chronic hepatitis C virus infection

Common side effects

Fatigue
Headache
Nausea

Key clinical trials

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Elbasvir Oral Granules CI brief — competitive landscape report
Elbasvir Oral Granules updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI